Rani Therapeutics (RANI) Expected to Announce Earnings on Wednesday

Rani Therapeutics (NASDAQ:RANI) will likely be issuing its quarterly earnings data before the market opens on Wednesday, March 19th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.

Rani Therapeutics Stock Performance

Shares of NASDAQ RANI opened at $1.51 on Monday. The stock has a fifty day moving average price of $1.49 and a two-hundred day moving average price of $1.93. The company has a debt-to-equity ratio of 2.34, a quick ratio of 1.60 and a current ratio of 1.60. The firm has a market cap of $86.51 million, a P/E ratio of -1.42 and a beta of 0.14. Rani Therapeutics has a 1 year low of $1.24 and a 1 year high of $8.75.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on RANI shares. HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Rani Therapeutics in a research note on Friday, February 7th. Canaccord Genuity Group restated a “buy” rating and issued a $9.00 target price on shares of Rani Therapeutics in a report on Wednesday, February 26th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $12.33.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.